Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

Schiellerup Jun. 16 at 8:13 PM

$SKYE $TCRX

0 · Reply

Schiellerup Jun. 12 at 11:17 AM

$TCRX In the second half of 2025, they are expected to initiate TSC-101 registration trial, presenting multiplex TCR-T therapy data and bringing updates on PLEXI-T and their ALOHA trial Good things to come

0 · Reply

Schiellerup Jun. 10 at 10:35 PM

$TCRX could look like we have to see a cooldown in RSI, before making further progress. 4th of june topped with a Daily RSI on 68.25. As long it Can hold above Daily MA75 at 1.543, we should see further increase in the nearest future. Let me know what you think Made a Long-position last week(could have made a better entry)

0 · Reply

dcme010711 Jun. 10 at 6:43 PM

$TCRX

0 · Reply

Schiellerup Jun. 5 at 10:13 PM

$TCRX What is people’s take on this?

0 · Reply

DanishViking92 Jun. 5 at 12:09 AM

$SKYE vs $TCRX Which one is most likely to move first?

0 · Reply

kshonstocks Jun. 3 at 6:52 PM

$TCRX off bottom on higher bottom

0 · Reply

MistaJT24 Jun. 3 at 3:55 PM

$TCRX Alexa play it seems like you're ready by R. Kelly.

0 · Reply

Charles927 May. 24 at 7:58 PM

$TCRX According to SEC filings dated May 21, 2025, major shareholder Weston Nichols acquired over 2.58 million shares over two consecutive days. Specifically, Nichols purchased 1,388,794 shares at $1.20 per share for approximately $1.67 million on May 19, followed by an additional 1.2 million shares at the same price for $1.44 million on May 20. The total investment amounts to $3.1 million.

1 · Reply

Charles927 May. 23 at 6:29 PM

$TCRX ☀️ EXTREMELY

0 · Reply

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 6, 2025, 7:00 AM EDT - 6 weeks ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 4:53 PM EDT - 7 weeks ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Mar 31, 2025, 7:00 AM EDT - 2 months ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 2 months ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 7, 2025, 11:31 AM EST - 3 months ago

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 5, 2025, 7:00 AM EST - 3 months ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 3 months ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 7:00 AM EST - 4 months ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 10, 2025, 3:14 AM EST - 4 months ago

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Dec 26, 2024, 7:00 AM EST - 6 months ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 6 months ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 9, 2024, 5:45 PM EST - 6 months ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 6 months ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 7 months ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 5, 2024, 9:15 AM EST - 8 months ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 9 months ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Aug 29, 2024, 7:00 AM EDT - 10 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

Aug 26, 2024, 10:09 AM EDT - 10 months ago

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 12, 2024, 7:00 AM EDT - 11 months ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 24, 2024, 4:05 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 1 year ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 1 year ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 1 year ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 1 year ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 1 year ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 4, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Dec 27, 2023, 7:00 PM EST - 1 year ago

TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value

Dec 9, 2023, 12:00 PM EST - 1 year ago

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Dec 7, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

Dec 4, 2023, 4:05 PM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

Dec 4, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

Nov 30, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

Nov 9, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Nov 2, 2023, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

Schiellerup Jun. 16 at 8:13 PM

$SKYE $TCRX

0 · Reply

Schiellerup Jun. 12 at 11:17 AM

0 · Reply

Schiellerup Jun. 10 at 10:35 PM

0 · Reply

dcme010711 Jun. 10 at 6:43 PM

$TCRX

0 · Reply

Schiellerup Jun. 5 at 10:13 PM

$TCRX What is people’s take on this?

0 · Reply

DanishViking92 Jun. 5 at 12:09 AM

$SKYE vs $TCRX Which one is most likely to move first?

0 · Reply

kshonstocks Jun. 3 at 6:52 PM

$TCRX off bottom on higher bottom

0 · Reply

MistaJT24 Jun. 3 at 3:55 PM

$TCRX Alexa play it seems like you're ready by R. Kelly.

0 · Reply

Charles927 May. 24 at 7:58 PM

1 · Reply

Charles927 May. 23 at 6:29 PM

$TCRX ☀️ EXTREMELY

0 · Reply

jdlman May. 22 at 11:48 AM

$TCRX

0 · Reply

baba_420 May. 22 at 2:56 AM

$TCRX when is data due ?

1 · Reply

MoneyMediary May. 22 at 2:04 AM

$TCRX Lynx1 Capital just doubled down—buying 2.59M shares at $1.20. That’s $3.1M into a biotech name already down 70%+ from its highs. They’ve been averaging down for months. Now they’ve sized up. https://moneymediary.com/p/insider-doubles-down-on-biotech-after-selloff

0 · Reply

SQUEAKSBANDIT May. 21 at 11:23 PM

$TCRX im not certain, but i believe the filing may be due to the conversion of prefunded warrants

0 · Reply

TradeIdeas1 May. 21 at 8:51 PM

$TCRX #tradeideas #MoneyMachine GOT ME IN - DASTING #stocks #stockmarket https://www.trade-ideas.com/share.php?code=Rw2uM7c5B6XKZAJ7AB2nrG5BKzT2Ou52

0 · Reply

soll May. 19 at 8:04 PM

$TCRX (per: Morgan Stanley) Maxwell Skor Morgan Stanley Buy 05/19/2025 $10.00

0 · Reply

soll May. 16 at 7:13 PM

$TCRX Justin Zelin (per: Morgan Stanley) BTIG Buy 05/07/2025 $12.00 Promising Clinical Differentiation and Strategic Advancements Drive Buy Rating for TScan Therapeutics - TipRanks.com

0 · Reply

FinJay May. 14 at 10:36 PM

$TCRX https://youtu.be/dPYnH0Im9As

0 · Reply

Stocks4thought May. 13 at 7:30 PM

$XLO $1.40 soon- great tech-love the CEO- market makers mucked it- validate tech by two partners. ot $TCRX $SLNO

0 · Reply

Stocks4thought May. 13 at 2:12 PM

$XLO $1.17 at least- market is dumb. Look at the data IL...... ot $TCRX - neglected- look at the data vs gaming by the street. OT $SLNO basis sub $3

0 · Reply

Stocks4thought May. 13 at 1:30 PM

$XLO Is a sympathy play- the game is rigged- hit jobs- $TCRX has good data- super undervalue. $CTMX

0 · Reply

Stocks4thought May. 12 at 6:19 PM

$TCRX The rate of the event is reduced by $70\%$.

0 · Reply

Market Cap	87.72M
Revenue (ttm)	2.82M
Net Income (ttm)	-127.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,521.28%
Debt to Equity Ratio	0.15

Volume	435,800
Avg Vol	596,122
Day's Range	N/A - N/A
Shares Out	56.59M
Stochastic %K	21%
Beta	0.98
Analysts	Strong Sell
Price Target	$9.00